Based on the forecast data, sales of Cardiac Glycosides in Australia are projected to exhibit consistency from 2024 to 2028, with values maintained at 0.1 US Dollars Per Capita. The series indicates a plateau without any year-on-year percentage variation, highlighting a stable demand over the forecast period. Data from 2023, while not provided in the query, is essential for evaluating historical performance and trend analysis. Given the stability observed in the values from 2024 onward, it is crucial to note that no compound annual growth rate can be calculated from these static values.
Future trends to watch for include potential market disruptors such as new treatment alternatives, changes in healthcare policies, or advancements in medical technology. Additionally, monitoring the impact of aging demographics and prevalence of cardiovascular diseases in Australia could provide insights into future market dynamics for Cardiac Glycosides.
